[ad_1]
Original title: The new corona vaccine you are interested in has been updated with “spoiler” …
As new corona pneumonia ravages the world, as the world’s largest offline international comprehensive exhibition in 2020, the third China Internationalto importThe exhibition opened as scheduled.
The biggest difference from previous sessions is that this year a new area for public health and epidemic prevention was established at the CIIE. “Anti-epidemic” has become a subject of heated debate, while “vaccine” has become a keyword that cannot be ignored.
《international financesThe newspaper learned from the CIIE site that the new corona vaccine targeting people around the world, including AstraZeneca,Sanofi、PfizerPharmaceutical giantsthe companyThey have shown their latest research results in the form of images or text at the CIIE.
What is the new corona vaccine like?
The new AZD1222 corona vaccine developed jointly by AstraZeneca and the University of Oxford is one of the fastest growing vaccines in the world. Currently, III clinical trials of this vaccine have been conducted in many countries and regions, including the United States, Great Britain, Brazil, South Africa and Japan. According to the competent person in charge of AstraZeneca, this vaccine is available in mainland China.marketR&D, production, supply anddealExclusiveAuthorizationgiveKangtai BioAnd the company is preparing workshop updates and equipment procurement for the new corona vaccine at the Shenzhen Guangming base.jobs。
Germany, leader in mRNA therapycompanyBuilding on its advantages in mRNA technology, Byntec started research and development of the new corona vaccine in January. Many candidate vaccines are currently in development. The relevant person in charge said, “The vaccine codenamed BNT162 has started a phase I clinical trial in Taizhou City, Jiangsu Province. All 144 subjects have completed two immunizations and the response is good.”
Although the vaccine has only reached phase I clinical trials, Biotech is confident in the development of its new corona vaccine. It is understood that the company has entered into an agreement withFosun PharmaSignedstrategyCooperation agreement, the latter is responsible for the new corona vaccine in ChinaproductDevelopment and commercialization.
And Janssen’s new corona vaccine, whose clinical trial was suspended due to a serious adverse event some time ago, is currently preparing to resume enrollment in the ENSEMBLE III clinical trial in the United States, with the goal of evaluating the dose vaccine. single and placebo in up to 60,000 adults 18 years and older. Safety and efficacy.
Compared to the new coronavirus vaccine mentioned above, which has a high degree of concern, vaccine research and development are “veterans”SanofiThe progress of research by Merck and Merck in the field of new crowns has received less attention from the outside world. The reporter learned from the scene,SanofiA cross-platform approach is being used to develop new vaccines that target coronavirus, including genes.ReorganizationVaccine technology and mRNA nucleic acid vaccine technology. Merck acquired the new coronary pneumonia vaccine research project from Themis Bioscience, which has entered a phase I clinical trial. At the same time, it also collaborated with IAVI on a new corona vaccine, which has now entered the phase I clinical trial.
In fact, in addition to antigens, innovative adjuvant technologies have also played an important role in the development of new corona vaccines. This is an additive often used in vaccines, which helps to improve the body’s immune response, thus obtaining stronger and longer-lasting immunity and improving the ability to resist infection.
Tang Haiwen, Head of GlaxoSmithKline’s (GSK) Chinese Medical Departmentto acceptThe “International Finance” journalist said in an interview: “GSK is working with Sanofi Pasteur and Clover BiopharmaceuticalLimited liability companyCooperation to provide the two with an adjuvant system in the development process of their new corona vaccine. Among them, the vaccine cooperated by GSK and Sanofi Pasteur has entered clinical phase III. It can be seen that the level of antibodies induced by it is very high, but it is temporarily impossible to determine whether the level of antibodies is directly related to the protective effect of the vaccine. Wait for the final clinical data. “
These vaccines are here first
Vaccine application plays an irreplaceable role in preventing disease and maintaining public health safety, and this is also one of the important reasons why the new corona vaccine has attracted so much attention. At this year’s CIIE booth, the aforementioned companies not only brought the latest advancements in their new corona vaccines, but they also brought in some innovative vaccines.
For example, the French company Sanofi brought in 3 vaccines, the genetically recombinant influenza vaccine Flublok, the complete ready-to-use six-part liquid vaccine Hexaxim and the new MenQuadfi tetravalent meningococcal conjugate vaccine. Among them, the first two products have been listed in many countries and regions, and MenQuadfi was approved for listing in the United States this year.
The Merck booth focused on the theme of “from prevention to treatment”, and focused on displaying the quadrivalent human papillomavirus vaccine, the nine-valent human papillomavirus vaccine, the pentavalent rotavirus vaccine and antirespiratory syncytial virus and dengue Vaccine development under development for the two viruses.
PfizerThe company launches its best-selling product, the 13-serotype pneumococcal polysaccharide conjugate vaccine (ProductName: Preliminary 13) was placed in the booth of the public health and epidemic prevention zone.At the same time, it also brought the 20-valent pneumococcal polysaccharide conjugate vaccine developed on its basis, and the preventionpopularQuadrivalent conjugate meningococcal vaccine for meningitis.
The British pharmaceutical company GlaxoSmithKline (GSK) brought the “Three Musketeers” to CIIE, and the Xin’anlix herpes zoster vaccine, the Cyrex human papillomavirus (HPV) vaccine, and the hepatitis B vaccine were instead. Currently, these three vaccines have been marketed in China. Among them, the herpes zoster vaccine is one of the first 48 “urgently needed new drugs” to be marketed abroad and rapidly introduced in China. Galen Award, known as the Bell Award.
(Source: International Finance News)
(Responsible editor: DF524)
I solemnly declare: The purpose of this information disclosed by Oriental Fortune.com is to spread more information and has nothing to do with this booth.
[ad_2]